$ZNTL
Zentalis Pharmaceuticals, Inc.

2021 Q2 Form 10-Q Financial Statement

#000172516021000183 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.36M $9.920M
YoY Change 4.46%
% of Gross Profit
Research & Development $44.77M $17.45M
YoY Change 156.53% 100.85%
% of Gross Profit
Depreciation & Amortization $119.0K $38.00K
YoY Change 213.16% 58.33%
% of Gross Profit
Operating Expenses $55.13M $27.38M
YoY Change 101.39% 157.41%
Operating Profit -$55.13M -$27.38M
YoY Change 101.39% 157.41%
Interest Expense $115.0K $80.00K
YoY Change 43.75%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$55.02M -$27.29M
YoY Change 101.59% 157.81%
Income Tax $45.00K $0.00
% Of Pretax Income
Net Earnings -$54.57M -$26.86M
YoY Change 103.2% 156.51%
Net Earnings / Revenue
Basic Earnings Per Share -$1.34 -$0.78
Diluted Earnings Per Share -$1.34 -$0.78
COMMON SHARES
Basic Shares Outstanding 40.74M shares 34.35M shares
Diluted Shares Outstanding 40.74M shares 34.35M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $250.9M $233.2M
YoY Change 7.59%
Cash & Equivalents $49.17M $96.02M
Short-Term Investments $201.7M $137.2M
Other Short-Term Assets $8.544M $5.200M
YoY Change 64.31%
Inventory
Prepaid Expenses
Receivables $5.000K $73.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $259.4M $238.5M
YoY Change 8.79%
LONG-TERM ASSETS
Property, Plant & Equipment $2.251M $481.0K
YoY Change 367.98%
Goodwill $3.736M $3.736M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.531M $3.600M
YoY Change 136.97%
Total Long-Term Assets $24.51M $18.74M
YoY Change 30.83%
TOTAL ASSETS
Total Short-Term Assets $259.4M $238.5M
Total Long-Term Assets $24.51M $18.74M
Total Assets $284.0M $257.2M
YoY Change 10.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.273M $4.217M
YoY Change 96.18%
Accrued Expenses $25.30M $11.35M
YoY Change 122.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.58M $15.57M
YoY Change 115.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $296.0K $1.262M
YoY Change -76.55%
Total Long-Term Liabilities $296.0K $1.262M
YoY Change -76.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.58M $15.57M
Total Long-Term Liabilities $296.0K $1.262M
Total Liabilities $36.35M $19.29M
YoY Change 88.44%
SHAREHOLDERS EQUITY
Retained Earnings -$305.3M -$126.0M
YoY Change 142.35%
Common Stock $41.00K $36.00K
YoY Change 13.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $223.8M $213.2M
YoY Change
Total Liabilities & Shareholders Equity $284.0M $257.2M
YoY Change 10.4%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$54.57M -$26.86M
YoY Change 103.2% 156.51%
Depreciation, Depletion And Amortization $119.0K $38.00K
YoY Change 213.16% 58.33%
Cash From Operating Activities -$46.11M -$22.03M
YoY Change 109.31%
INVESTING ACTIVITIES
Capital Expenditures -$815.0K -$30.00K
YoY Change 2616.67%
Acquisitions
YoY Change
Other Investing Activities $67.43M -$137.2M
YoY Change -149.13%
Cash From Investing Activities $66.60M -$137.3M
YoY Change -148.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -316.0K 191.7M
YoY Change -100.16%
NET CHANGE
Cash From Operating Activities -46.11M -22.03M
Cash From Investing Activities 66.60M -137.3M
Cash From Financing Activities -316.0K 191.7M
Net Change In Cash 20.17M 32.37M
YoY Change -37.68%
FREE CASH FLOW
Cash From Operating Activities -$46.11M -$22.03M
Capital Expenditures -$815.0K -$30.00K
Free Cash Flow -$45.30M -$22.00M
YoY Change 105.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001725160
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39263
dei Entity Registrant Name
EntityRegistrantName
Zentalis Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3607803
dei Entity Address Address Line1
EntityAddressAddressLine1
530 Seventh Avenue,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2201
dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10018
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
433-3791
dei Security12b Title
Security12bTitle
Common Stock,$0.001 par value per share
dei Trading Symbol
TradingSymbol
ZNTL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45052904 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49170000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54951000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
201730000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
283554000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
417000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8301000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6182000 USD
CY2021Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
243000 USD
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
259449000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
345104000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2251000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1099000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1195000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2520000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
4794000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2976000 USD
CY2021Q2 us-gaap Deferred Costs
DeferredCosts
716000 USD
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
0 USD
CY2021Q2 us-gaap Goodwill
Goodwill
3736000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
3736000 USD
CY2021Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8800000 USD
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8800000 USD
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3021000 USD
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1320000 USD
CY2021Q2 us-gaap Assets
Assets
283962000 USD
CY2020Q4 us-gaap Assets
Assets
365555000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8273000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8661000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25304000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19940000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
33577000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28601000 USD
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2480000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2480000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
296000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1097000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
36353000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
32178000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41314864 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41314864 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41040286 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41040286 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
41000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
41000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
529019000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
509339000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
94000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
36000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-305309000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17452000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83164000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200834000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
223845000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
308582000 USD
CY2021Q2 us-gaap Minority Interest
MinorityInterest
23764000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
24795000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
247609000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
333377000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
283962000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365555000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44770000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30710000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10362000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9924000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22315000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13065000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
55132000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
27376000 USD
us-gaap Operating Expenses
OperatingExpenses
105479000 USD
us-gaap Operating Expenses
OperatingExpenses
43775000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-55132000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27376000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-105479000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-43775000 USD
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
115000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
84000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
214000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
248000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55017000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27292000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-105265000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43527000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
45000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
241000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-55062000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-27292000 USD
us-gaap Profit Loss
ProfitLoss
-105506000 USD
us-gaap Profit Loss
ProfitLoss
-43527000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-488000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-435000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1031000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-544000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-54574000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-26857000 USD
us-gaap Net Income Loss
NetIncomeLoss
-104475000 USD
us-gaap Net Income Loss
NetIncomeLoss
-42983000 USD
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.53
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40738000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40738000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34353000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34353000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40549000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40549000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16978000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16978000 shares
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-55062000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-27292000 USD
us-gaap Profit Loss
ProfitLoss
-105506000 USD
us-gaap Profit Loss
ProfitLoss
-43527000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
45000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
45000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
13000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-55018000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-27288000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-105448000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-43523000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-488000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-435000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1031000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-544000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54530000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26853000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-104417000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42979000 USD
us-gaap Profit Loss
ProfitLoss
-105506000 USD
us-gaap Profit Loss
ProfitLoss
-43527000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
198000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
76000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19610000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8010000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
521000 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
65000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-412000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-67000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3937000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4796000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4838000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1212000 USD
zntl Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
267000 USD
zntl Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-11000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83582000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38904000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
77812000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
137236000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
159128000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1255000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
80061000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-137292000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
172482000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
70000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 USD
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
18424000 USD
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0 USD
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
14228000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
386000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-316000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
205134000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3837000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28938000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56271000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67489000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52434000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96427000 USD
zntl Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
0 USD
zntl Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
70000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
330000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49170000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96016000 USD
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
3264000 USD
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
411000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52434000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
96427000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292638000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9919000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
44000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70000 USD
CY2021Q2 us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
1000 shares
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-488000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-54574000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
247609000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
333377000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19610000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
58000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70000 USD
us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
1000 shares
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1031000 USD
us-gaap Net Income Loss
NetIncomeLoss
-104475000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
247609000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-89191000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
172365000 USD
CY2020Q2 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
18424000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7681000 USD
CY2020Q2 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
155934000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4000 USD
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-435000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-26857000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
237925000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-73285000 USD
zntl Temporary Equity Stock Issued During Period Shares New Issues
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
867000 shares
us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
14228000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
172365000 USD
us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
18424000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8010000 USD
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
155934000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-544000 USD
us-gaap Net Income Loss
NetIncomeLoss
-42983000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
237925000 USD
CY2017Q4 zntl Common Stock Conversion Ratio
CommonStockConversionRatio
1
CY2020Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
190000000.0 USD
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
17600000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div>
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
201681000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
201730000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
283518000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
283554000 USD
CY2021Q2 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
201730000 USD
CY2020Q4 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
247455000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
36099000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
201730000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
283554000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
29346000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
29015000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
201730000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
283554000 USD
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
231076000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
312569000 USD
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
2338000 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1021000 USD
CY2021Q2 zntl Prepaid Software License And Maintenance
PrepaidSoftwareLicenseAndMaintenance
385000 USD
CY2020Q4 zntl Prepaid Software License And Maintenance
PrepaidSoftwareLicenseAndMaintenance
563000 USD
CY2021Q2 zntl Foreign Research And Development Credit Refund
ForeignResearchAndDevelopmentCreditRefund
1148000 USD
CY2020Q4 zntl Foreign Research And Development Credit Refund
ForeignResearchAndDevelopmentCreditRefund
692000 USD
CY2021Q2 zntl Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
8100000 USD
CY2020Q4 zntl Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
5963000 USD
CY2021Q2 us-gaap Interest Receivable
InterestReceivable
327000 USD
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
478000 USD
CY2021Q2 zntl Other Prepaid Expense
OtherPrepaidExpense
797000 USD
CY2020Q4 zntl Other Prepaid Expense
OtherPrepaidExpense
441000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
13095000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
9158000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
4794000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2976000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8301000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6182000 USD
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2698000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1349000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
447000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
250000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2251000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1099000 USD
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
119000 USD
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
198000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
76000 USD
CY2021Q2 zntl Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
16640000 USD
CY2020Q4 zntl Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
11947000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6389000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5649000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
785000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0 USD
CY2021Q2 zntl Accrued General And Administrative Costs Current
AccruedGeneralAndAdministrativeCostsCurrent
126000 USD
CY2020Q4 zntl Accrued General And Administrative Costs Current
AccruedGeneralAndAdministrativeCostsCurrent
996000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
804000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
902000 USD
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
560000 USD
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
410000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
36000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25304000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19940000 USD
CY2021Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2021Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
zntl Convertible Preferred Stock Dividends Per Share Declared
ConvertiblePreferredStockDividendsPerShareDeclared
0
zntl Temporary Equity Automatic Conversion Feature Gross Cash Proceeds Minimum Amount Received In A Public Offering
TemporaryEquityAutomaticConversionFeatureGrossCashProceedsMinimumAmountReceivedInAPublicOffering
75000000.0 USD
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5187554 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5187554 shares
CY2017Q4 zntl Common Stock Shares Subject To Future Vesting Provisions
CommonStockSharesSubjectToFutureVestingProvisions
406831 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9919000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7681000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19610000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8010000 USD
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9919000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7681000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19610000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8010000 USD
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
205424 shares
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
534000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
637000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1171000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
72000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1099000 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
zntl Lessee Operating Lease Lease Not Yet Commenced Number Of Contracts
LesseeOperatingLeaseLeaseNotYetCommencedNumberOfContracts
2 lease
CY2021Q2 zntl Lessee Operating Lease Lease Not Yet Commenced Liability
LesseeOperatingLeaseLeaseNotYetCommencedLiability
105900000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-54574000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-26857000 USD
us-gaap Net Income Loss
NetIncomeLoss
-104475000 USD
us-gaap Net Income Loss
NetIncomeLoss
-42983000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40738000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40738000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34353000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34353000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40549000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40549000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16978000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16978000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5148000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4195000 shares

Files In Submission

Name View Source Status
0001725160-21-000183-index-headers.html Edgar Link pending
0001725160-21-000183-index.html Edgar Link pending
0001725160-21-000183.txt Edgar Link pending
0001725160-21-000183-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zentalis10-qq22021ex311.htm Edgar Link pending
zentalis10-qq22021ex312.htm Edgar Link pending
zentalis10-qq22021ex321.htm Edgar Link pending
zentalis10-qq22021ex322.htm Edgar Link pending
zntl-20210630.htm Edgar Link pending
zntl-20210630.xsd Edgar Link pending
zntl-20210630_cal.xml Edgar Link unprocessable
zntl-20210630_def.xml Edgar Link unprocessable
zntl-20210630_htm.xml Edgar Link completed
zntl-20210630_lab.xml Edgar Link unprocessable
zntl-20210630_pre.xml Edgar Link unprocessable